AXSM Overview
Upcoming Projects (AXSM)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AXSM)
-
Discussing the potential of AXS-12 (reboxetine), a norepinephrine reuptake inhibitor and cortical dopamine modulator, and the data from Phase 3 ENCORE trial in patients with narcolepsy with cataplexy.
Ticker: AXSM
Executed On: Dec 17, 2024 at 01:00 PM EST -
An updated discussion of Axsome's AXS-12 (reboxetine) a selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy and cataplexy after the release of its phase 3 data.
Ticker: AXSM
Executed On: Mar 29, 2024 at 11:30 AM EDT -
A Third Look: Reviewing the standard of care for bipolar depression and the use of Auvelity and Caplyta
Tickers: AXSM, ITCI
Executed On: Nov 17, 2023 at 12:00 PM EST -
A Second Look: Reviewing the standard of care for bipolar depression and the use of Auvelity and Caplyta
Tickers: AXSM, ITCI
Executed On: Nov 09, 2023 at 10:30 AM EST -
Reviewing the standard of care for bipolar depression and the use of Auvelity and Caplyta
Tickers: AXSM, ITCI
Executed On: Nov 09, 2023 at 08:15 AM EST -
Discovering the potential of Axsome's AXS-12 (reboxetine) a selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy and cataplexy after the release of its phase 2 data.
Ticker: AXSM
Executed On: Dec 15, 2022 at 05:45 PM EST -
A Third View: Discussing the potential of Axsome's AXS-05 (dextromethorphan-bupropion) for smoking cessation
Ticker: AXSM
Executed On: Dec 13, 2022 at 12:00 PM EST -
A fourth look: Discussing the current treatment landscape for ADHD and the potential of SUNOSI(solriamfetol), a dopamine and norepinephrine reuptake inhibitor
Ticker: AXSM
Executed On: Dec 09, 2022 at 03:30 PM EST -
A Second Perspective: Discussing the potential of Axsome's AXS-05 (dextromethorphan-bupropion) for smoking cessation
Ticker: AXSM
Executed On: Dec 09, 2022 at 12:00 PM EST -
Discussing the potential of Axsome's AXS-05 (dextromethorphan-bupropion) for smoking cessation
Ticker: AXSM
Executed On: Dec 08, 2022 at 02:30 PM EST -
A third look: Discussing the current treatment landscape for ADHD and the potential of SUNOSI(solriamfetol), a dopamine and norepinephrine reuptake inhibitor
Ticker: AXSM
Executed On: Dec 07, 2022 at 03:00 PM EST -
A second look: Discussing the current treatment landscape for ADHD and the potential of SUNOSI(solriamfetol), a dopamine and norepinephrine reuptake inhibitor
Ticker: AXSM
Executed On: Dec 07, 2022 at 02:00 PM EST -
A Fourth Look at the efficacy of AXS-05 in the treatment of Alzheimer's Disease Agitation
Ticker: AXSM
Executed On: Dec 01, 2022 at 06:30 PM EST -
A Third Look at the efficacy of AXS-05 in the treatment of Alzheimer's Disease Agitation
Ticker: AXSM
Executed On: Dec 01, 2022 at 03:30 PM EST -
A Second Look at the efficacy of AXS-05 in the treatment of Alzheimer's Disease Agitation
Ticker: AXSM
Executed On: Nov 30, 2022 at 01:15 PM EST -
A First Look at the efficacy of AXS-05 in the treatment of Alzheimer's Disease Agitation
Ticker: AXSM
Executed On: Nov 30, 2022 at 09:30 AM EST -
Discussing the standard of care and the potential of SUNOSI (solriamfetol) in treating excessive daytime sleepiness
Ticker: AXSM
Executed On: Nov 29, 2022 at 12:00 PM EST -
Discussing the current treatment landscape for ADHD and the potential of SUNOSI(solriamfetol), a dopamine and norepinephrine reuptake inhibitor
Ticker: AXSM
Executed On: Nov 28, 2022 at 11:00 AM EST -
A second look: Discussing the potential of Axsome's drug AXS-14 (esreboxetine) for the treatment of Fibromyalgia.
Ticker: AXSM
Executed On: Nov 23, 2022 at 03:00 PM EST -
Discussing the potential of Axsome's drug AXS-14 (esreboxetine) for the treatment of Fibromyalgia.
Ticker: AXSM
Executed On: Nov 21, 2022 at 12:00 PM EST -
A third look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Tickers: RLMD, JNJ, AXSM
Executed On: Aug 31, 2022 at 04:00 PM EDT -
A second look at Relmada Therapeutics' novel NMDAR channel blocker, REL-1017, as monotherapy for the treatment of MDD and its P2 data
Tickers: RLMD, JNJ, AXSM, SAGE
Executed On: Aug 30, 2022 at 06:30 PM EDT -
A Fourth View: Looking at the standard of care and development of AXS-05 in treating patients with major depressive disorder (MDD)
Ticker: AXSM
Executed On: Jul 29, 2022 at 12:15 PM EDT -
A Third View: Looking at the standard of care and development of AXS-05 in treating patients with major depressive disorder (MDD)
Ticker: AXSM
Executed On: Jul 21, 2022 at 03:00 PM EDT -
A Second View: Looking at the standard of care and development of AXS-05 in treating patients with major depressive disorder (MDD)
Ticker: AXSM
Executed On: Jun 27, 2022 at 03:00 PM EDT -
Looking at the standard of care and development of AXS-05 in treating patients with major depressive disorder (MDD)
Ticker: AXSM
Executed On: Jun 24, 2022 at 03:00 PM EDT -
A Second Look: Discussing the potential of AXS-07, an oral multi-mechanistic investigational medicine for the acute treatment of migraine
Ticker: AXSM
Executed On: Mar 18, 2022 at 04:00 PM EDT -
Discussing the potential of AXS-07, an oral multi-mechanistic investigational medicine for the acute treatment of migraine
Ticker: AXSM
Executed On: Mar 18, 2022 at 09:00 AM EDT
Upcoming & Overdue Catalysts (AXSM)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (AXSM)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
